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Over the past years, periodic meetings to discuss
various elephant health concerns have been hosted
in the U.S. These meetings have brought together
elephant managers, veterinarians, scientists,
federal and state regulatory veterinarians, public
health officials, and human infectious disease
experts. Tuberculosis (TB; mostly Mycobacterium
tuberculosis in the U.S.) in elephants has been a
focus of some of these meetings because of its
high profile and the extensive resources currently
invested in this issue. Nevertheless, the degree to
which TB compromises elephant health remains
unclear; yet large sums of funding are spent on
the diagnosis, treatment, and management of TB,
diverting potential resources from conservation.
In the context of Asian elephant conservation,
managing disease and other health issues calls for
an assessment of the risks to the species versus the
allocation of available resources. Epidemiologists
view disease as the interactions between hosts
(i.e. immune system function), agents (i.e. TB
and other infectious and noninfectious causes of
disease), and the environment. Environmental
contributions to the development of disease in
elephants include poor nutritional resources,
and presumed stress associated with factors such
as habitat loss, increased habitat sharing with
domestic animals, and human-elephant conflict.
Environmental contributions to disease are
particularly important to consider for free-ranging
wildlife, including elephants, because they are
often the most realistic points of intervention for
disease control in these populations. It is more
practical to manage the environment to optimize
elephant health and minimize transmission of
infectious agents, than it is to treat free-ranging
elephant populations for diseases such as TB.
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Elephant conservation should always consider
overall elephant population health and welfare,
and objectively apply sound science to balance
health risks and resources to achieve the most
benefit. While evidence-based medicine is
increasingly accepted as a sound approach
for animals and humans, there are substantial
challenges in conducting rigorous research for
many of the problems faced by elephants. This
often results in basing management decisions on
research studies with designs that have limited
application to the question at hand.
The extent to which elephant (population and
individual) health is affected by TB has not
been clearly documented, yet in recent years
large amounts of resources have been spent
on this specific issue. This is a concern in
Asian range countries where resources are
very limited. Elephant health management
programs that emphasize the risks of a single
disease without first assessing the risks of other
health and conservation concerns, relative to
the benefits of various management strategies,
will result in misallocation of resources and
ultimately undermine elephant conservation
efforts. In other words, disease management
strategies need to consider ”the big picture”, be
based on rigorous science, and use transparent
and objective strategies for balancing risks
and benefits for various management plans
and the corresponding allocations of funding.
Comprehensive assessments of TB, relative to
other health and conservation challenges, have
not been conducted for elephants.
Central concerns since the first recognition of
TB in elephants include: individual elephant

welfare, occupational risks to those working with
elephants, and public health risks. These concerns
present complex challenges. In part, this is due to
the biology of the organism (a chronic infection
that is difficult to diagnose); differing viewpoints
on animal welfare in a dynamic animal welfare
and animal rights environment; perceived or real
human health risks; the challenges of developing
rigorous scientific projects on small populations
of endangered species; and a complex regulatory
environment in some countries. Much
confusion has resulted from debate regarding
the strengths and weaknesses of various testing
methods (culture and serology/blood testing);
incorrect published estimates of TB prevalence;
uncertainty about effective drugs and side effects
for elephants with TB; and other factors. This
confusion is of particular concern where elephant
or human welfare, and elephant conservation can
be compromised or limited.

number corresponds to about one new case per
year. Consequently, incorrect estimates of the
percentage of TB infected elephants inaccurately
skew perceptions and understanding of the actual
prevalence of active TB infections in elephant
populations.
* To date, there is no science-based definition of
“exposure” to differentiate high-risk transmission
situations for elephants from those with little or
no risk. There is a gap in knowledge about factors
that assist in decisions affecting the management
of TB infected or exposed elephants. To address
this topic, an epidemiological survey of all
elephants in the U.S. is currently underway. The
results of this survey will provide information to
assist with management of TB in this population,
and serve as a guide for resolving this issue.

Some key points about TB and elephants

* Risks of TB transmission are also relevant to
humans. Human exposure risks must clearly
distinguish between the risks for those working
with and handling elephants (occupational health),
and health risks for members of the public that
are near to but not in close contact with elephants,
particularly in open air settings. Anecdotally,
elephant managers and veterinarians, most of
whom are regularly tested for TB, say that the
occupational health risks are low for elephant
handlers working with TB infected elephants in
the U.S. However, objective data should answer
this question, and this will be addressed with a
retrospective study of the occupational health
risks that is now in progress.

* Incorrect information has been presented in the
literature (e.g. Mikota & Maslow 2011) regarding
the prevalence of TB in elephants. It has been
stated that 18% of the U.S. Asian elephant
population is infected with TB. However, this is
a cumulative figure that does not use accepted
epidemiological calculations because it includes
elephants that are no longer living, while also
failing to retroactively exclude elephants that
have been “cleared” of active TB infection post
treatment. As of January 1, 2012, the prevalence
of TB in Asian elephants in the U.S. is closer to
5%. There have been no significant changes in
the number of newly culture positive animals on
an annual basis over the past decade, and this

* There is still no conclusive evidence to show
the definitive direction of TB transmission
between humans and elephants. In humans,
M. tuberculosis is not highly transmissible,
even within a household. It is well understood
in human medicine that the disease spreads
exclusively through aerosolization; this suggests
that the same applies to elephants and that fomite
(i.e. from touching objects such as feed tubs)
transmission may be minimal or nonexistent.
Furthermore there have been no documented
cases of members of the public becoming TB
infected from an elephant. Therefore it appears
that elephants with M. tuberculosis infections
pose a very low public health risk.

There is a need for improved information and
clarity on the key issues. In order to objectively
and scientifically address concerns about TB,
professional elephant stakeholders have discussed
and support the implementation of several focal
studies, currently underway. Additionally, a
comprehensive study has been initiated that will
review animal welfare, experimental design,
current elephant TB literature, and regulatory
concerns, with the intent of providing focus to
future research and TB management guidelines.
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* Serology has not proven to be an effective
diagnostic tool for TB in humans or for M. bovis
control programs. Serology is not a part of M.
bovis control programs for cattle in the U.S.
Similarly, a World Health Organization (WHO)
report (2011) on the use of serology for detection
of active TB infection in humans indicates that
they are not accurate or consistent predictors
of infection. As a result, in 2012 India became
the first country to ban TB serology diagnostic
tests for humans, with a notification issued by
the Ministry of Health and Family Welfare.
Serology tests for TB in elephants, the StatPak
and MAPIA, have been heavily promoted and
proposed to be highly accurate. However the
sensitivity and specificity of these tests have
been evaluated only at the extremes of known
non-infected and known late stage infected
elephants. For all other elephants, the sensitivity,
specificity, and predictive value have not been
determined. Based on other species and anecdotal
evidence of false positives and negatives in U.S.
captive elephants, it is likely that the accuracy
of serologic tests for elephants is less than is
currently marketed. Therefore, serology results
alone should not be the basis for classifying
elephants as TB “positive”, and treatment based
on serology alone can be questioned in the
absence of supporting evidence or concerns.
* While there has been considerable focus
on diagnostic tests for TB in elephants, little
attention has been given to treatment. The
current treatment regimen for TB in elephants
is very costly, long term, can have severe side
effects on the elephant being treated, and requires
significant veterinary oversight. There is still
insufficient identification of pathologies resulting
from adverse anti-tuberculosis drug effects;
optimal routes for administration of medications
have not been clarified; and better parameters
for evaluating treatment success (blood levels
of drugs are currently used) have not been
addressed. Maintaining open communication
for updates on recent developments in human
TB treatments is useful. A new pharmacokinetic
study of the drugs used in treating tuberculosis in
elephants is currently underway in the U.S, and
resulting data will contribute to the development
of improved treatment protocols.
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In Asian elephant conservation, an existing and
important concern is how to best invest resources
to improve elephant health. Limited resources are
available for use on broad elephant conservation
issues, i.e. habitat protection, conflict mitigation,
etc. While individual animal welfare needs often
gain attention, the challenge is balancing large
investments in individual animals’ needs as well as
use of resources to more broadly benefit elephant
populations. To better assess factors that limit
the ability to address overall elephant health and
management concerns in Asia, a study surveying
local veterinarians was initiated to place various
medical conditions and infrastructure needs in
context. Rather than focus on a single disease, as
discussed above, the survey is intended to address
all health and management concerns that impact
captive and free-ranging elephant populations in
Asia. Currently, almost fifty surveys from most
of the Asian elephant range countries are being
analyzed, and results will be published. Given the
many challenges facing elephants in Asian range
countries, such as habitat loss, human-elephant
conflict, and other factors that increase elephant
mortality rates and decrease reproduction, this
survey will serve as a starting point for identifying
resource investments that will provide the most
population benefit. This is analogous to investing
resources into preventive care and common
diseases in human populations, rather than into
uncommon but expensive diseases, to achieve the
greatest benefit to the population with existing
resources. Consequently, this survey’s broadbased approach is critical for placing potential
health risks in perspective, and identifying
strategies that will effectively improve the health
and welfare of elephants in Asia.
When addressing elephant health, in particular
where it impacts conservation strategies, we
encourage the conservation community to
carefully assess all of the factors that contribute
to the development of diseases, and objectively
and transparently evaluate the relative risks and
allocation of resources. We anticipate that these
aforementioned studies will not only clarify
appropriate strategies for addressing TB concerns
in elephants, but also identify the best ways to
invest existing resources to truly benefit Asian
elephant health and conservation.

